Product image of Latanoprost Demo (Latanoprost) supplied by GNH India

Latanoprost Demo

Active Ingredient:
Latanoprost
Origin:
EU

Latanoprost Demo (Latanoprost)

Latanoprost, the active ingredient in Latanoprost Demo, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It works by increasing uveoscleral outflow of aqueous humor, thereby reducing intra‑ocular pressure in adults diagnosed with primary open‑angle glaucoma or ocular hypertension.

GNH India supplies Latanoprost Demo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory conformity across global markets. The product meets EU pharmacopeial standards and is manufactured under strict Good Manufacturing Practice guidelines.

Manufacturer / TM Owner

Demo Abee

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Latanoprost is indicated for conditions affecting aqueous humor dynamics within the open‑angle glaucoma disease family.

  • Primary open‑angle glaucoma: reduces intra‑ocular pressure, helping to slow visual field loss.
  • Ocular hypertension: lowers pressure to prevent progression to glaucoma.
  • Open‑angle glaucoma (including pseudoexfoliative): improves pressure control when other agents are insufficient.

How It Works

  • Latanoprost binds to prostaglandin F‑type (FP) receptors on the ciliary muscle and scleral tissue, activating a cascade that remodels extracellular matrix and enhances uveoscleral outflow of aqueous humor. The increased outflow reduces intra‑ocular pressure, addressing the primary pathogenic factor in open‑angle glaucoma and ocular hypertension. The drug’s selective FP receptor agonism avoids significant systemic prostaglandin activity, allowing topical administration with localized ocular effect.

Side Effects

Latanoprost may cause ocular and peri‑ocular reactions, most of which are mild and transient.

Common Side Effects

  • Eye redness: mild conjunctival hyperemia.
  • Increased eyelash growth: longer, thicker lashes.
  • Iris darkening: gradual increase in brown pigment.
  • Eye irritation: foreign body sensation or mild itching.

Serious or Rare Side Effects

  • Uveitis: inflammation of the uveal tract requiring medical attention.
  • Macular edema: swelling of the central retina that can affect vision.

Precautions & Warnings

Before prescribing Latanoprost, clinicians should consider several precautionary measures to ensure safe use.

  • Pregnancy: Category C; use only if potential benefit justifies potential risk to the fetus.
  • Breastfeeding: Caution; limited data, weigh benefits against possible infant exposure.
  • Active ocular inflammation: Contraindicated; avoid use during uveitis or viral keratitis.
  • History of cystoid macular edema: Monitor closely; may exacerbate retinal swelling.
  • Concomitant ocular surgery: Delay use until wound healing is complete.
  • Store at room temperature: Keep the bottle tightly closed, protect from light and freezing.

Avoid Interactions

Latanoprost can interact with other ophthalmic or systemic agents, influencing efficacy or safety.

Major Interactions (Avoid)

  • Use with other prostaglandin analog eye drops: additive effect may increase risk of ocular side effects.
  • Combination with ocular hyperemia‑inducing agents (e.g., epinephrine): may worsen redness and discomfort.

Moderate Interactions (Monitor Closely)

  • Beta‑blocker eye drops: additive intra‑ocular pressure reduction; monitor IOP.
  • Alpha‑agonist eye drops: potential enhanced pressure‑lowering effect; adjust therapy as needed.
  • Systemic carbonic anhydrase inhibitors: combined IOP‑lowering may be excessive; observe pressure.
  • Non‑steroidal anti‑inflammatory eye drops: may affect corneal healing; watch for irritation.

Frequently Asked Questions

Latanoprost Demo is an ophthalmic solution used to lower intra‑ocular pressure in adults with primary open‑angle glaucoma or ocular hypertension. By reducing pressure, it helps to slow disease progression and protect visual function.

Latanoprost acts as an agonist at prostaglandin F‑type (FP) receptors in the eye, promoting remodeling of extracellular matrix and increasing uveoscleral outflow of aqueous humor. This enhanced outflow lowers intra‑ocular pressure, the main therapeutic target in glaucoma management.

The dosing regimen is determined by the prescribing clinician. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact schedule should follow the prescriber’s instructions.

Latanoprost is classified as pregnancy category C, meaning it should only be used if the potential benefit justifies any potential risk to the fetus. Limited data are available for breastfeeding; caution is advised and the decision should be based on a risk‑benefit assessment.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Latanoprost belongs to the prostaglandin analog class, which generally offers once‑daily dosing and strong intra‑ocular pressure reduction. Compared with beta‑blocker or carbonic anhydrase inhibitor drops, prostaglandin analogs often have a more favorable dosing convenience and comparable efficacy, though side‑effect profiles differ.

The product should be stored at room temperature, away from direct sunlight and freezing conditions. Keep the bottle tightly closed when not in use, protect it from moisture, and discard any solution that appears discolored or contaminated.

Latanoprost is applied as a single drop into the conjunctival sac of the affected eye(s) once daily, usually in the evening. Patients should avoid touching the tip of the bottle to the eye or any other surface to maintain sterility.

Serious but rare risks include uveitis and macular edema, both of which can affect vision and require prompt medical evaluation. Any sudden loss of visual acuity, severe eye pain, or persistent redness should be reported to a healthcare professional immediately.

Latanoprost is contraindicated in patients with active ocular inflammation such as uveitis or viral keratitis. Individuals with known hypersensitivity to latanoprost or any component of the formulation should also avoid its use.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Latanoprost

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT